NASP Speciality Pharmacy Podcast

Why Rare-Ultra Orphan Therapies need early Market Access planning and innovative solutions | Ascella Health

Success in launching new therapies for rare diseases (RDs) implies the ability for the manufacturer to achieve a level of reimbursed price and a level of market access that are commercially viable on the market. Access to RD therapies is challenging because the legal and policy frameworks may be absent, funding may be insufficient and/or payers do not see the justification with the prices for these therapies. The industry has, however, a real opportunity to partner with healthcare stakeholders.  There needs to be continued support to provide the education towards payers, drive evidence-based pricing, and innovative contracting, and address the multiple hurdles of access for these unique therapies. But how do we price and how do we gain access on the promise of long-term value when we don’t have the long-term data on these new therapies?  That is why all stakeholders need to address early market access planning, including inclusive data collection, payer models and the impact of new regulations and innovative trial design on data collection and ongoing evidence provision.
           
Podcast Participants: Jim Clement – Partner & Board Member at Coeus Holdings
                                       Donovan Quill – Executive Vice President at Terebellum

Insights into the (GCT) Gene/Cell Therapy market & challenges facing market entrants and commercialization | Ascella Health

Continuing advances in cell and gene therapy (CGT) are transforming the pharmacy and point of care ecosystem. Recent launches of new CGTs have yielded mixed results on getting the right therapy to the right patients.  The CGTs pipeline and approvals are likely to rise dramatically in the near future. In 2024 alone, up to 21 cell therapy launches and as many as 31 gene therapy launches are on the horizon. Therefore, the launch readiness for these products should be effective so that the therapies can benefit as many patients as possible while ensuring a sufficient return on manufacturers’ investments. With so many new CGTs poised for commercialization, it’s imperative to consider innovative ways for a product launch that benefits CGTs patients. Ensuring that the market, the product, and the company itself are fully prepared for an effective launch will enable success.
 
Podcast Participants: Michelle Rice, CEO, Michelle Rice & Associates
Kenneth Mankowski, DO, FACN, MS Neurologist Specialist, CNS & MS InstituteHost: 
Michael Baldzicki
 

Talking Patient Experience Innovation with Noble | NASP

During this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, sits down with Tim McLeroy, Executive Director of Marketing & Patient Services at Noble. They discuss challenges patients face when beginning therapeutic treatment, solutions to provide the training and support that patients need, the impacts of biosimilars and telehealth on patient experience, and cost-effective approaches for patient training and onboarding.Sheila Arquette, RPh, President & CEO of NASP; Tim McLeroy, Executive Director of Marketing & Patient Services at Noble

Insights into the Rare-Ultra Orphan market & the challenges for manufacturers, providers, payers, pharmacies, and patients | NASP

Rare diseases affect nearly 10% of the US population and transformative changes to research and development, as well as modernized regulatory pathways, have accelerated the entry of orphan drugs to the market. This uptick has necessitated discussions on how best to manage these conditions to ensure the right therapy is provided to the right patient at the right time. This episode is a first step in creating an open and transparent dialogue on the challenges faced by insurers in a resource constrained healthcare environment. As the focus will offer listeners a view of the latest trends in rare disease / orphan drug market access, assessing current payer perspectives, and offering insights and potential implications of the management of rare disease and orphan drugs. By highlighting the key issues and opportunities, we hope that payers, providers, patients, and biopharmaceutical manufacturers will bridge the access gaps and ensure patients can receive medically necessary therapies to ultimately improve patient outcomes.

How to Improve the Patient Experience and Why it Matters | NASP

Please visit our website to listen to prior podcast 1, 2 & 3 at https://lnkd.in/gsrjnv9P
 
The Specialty Pharmacy Healthcare eco-systems is becoming more efficient in the way they intake and treat patients, and patients are becoming more well-informed. Efficient and accurate communication among doctors, nurses, support staff, and patients has never been more important. With streams of information constantly flowing, there are ample opportunities for the chain of communication to break down and become a barrier to care—meaning delays in care for patients, and bottlenecks to clinician productivity. Specialty Pharmacies are more collaborative with their patient-engagement teams capabilities that strengthen this point of care. These healthcare solutions enable team members to drive key decisions with confidence, no matter where they are. With the freedom to focus less on ordering a specialty prescription, tracking down supplies, or logging data, patient care teams can focus more on what matters most: the patients. Therefore, specialty pharmacies differ, not by location, but by services offered and conditions treated. When treating chronic and rare conditions, those differences add up to make a big impact on patient success. The specialty pharmacies are improving drug treatment outcomes and breaking down the barriers that make patient access difficult. Patients facing complex, chronic, rare, or life-threatening conditions rely on the added support and resources a specialty pharmacy provides

Optimizing Specialty Pharmacy Health Outcomes | NASP

The healthcare sectors are recognizing the value of innovative and effective strategies to address the challenges of managing specialty drugs, which treat complex, chronic or rare conditions and require special administration or handling. As a strategy to control the costs associated with managing a complex patient population, the market is turning to value-based contracting, which links reimbursement or payment for aproduct to positive clinical outcomes. These trends have paved the way for an increase in limited distribution drugs (LDDs), or therapies only made available to a small number of specialty pharmacies, to give manufacturers greater oversight and control over the quality of patient care and support. Specialty drugs are the future of medicine, but they require high-touch care coordination and concerted follow-up to ensure patients remain adherent and can manage potential side effects to realize the full value of therapy.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Understanding Patient Care Coordination Across the Healthcare SpectrumPodcast | NASP

Participants: Mike Baldzicki (AscellaHealth), Kollet Koulianos (VP, NHF) and Dr. Ken Mankoski (Neurologist – MS)
Learn more about your ad choices. Visit megaphone.fm/adchoices

The Value of Embedded Specialty Pharmacists | NASP Podcast

Participants and Roles:
·            Sheila Arquette, President & CEO, NASP -- Host
·            Ana Simonyan, PharmD, BCACP – Infectious Diseases -- Interviewer
·            Cody A. Chastain, MD – Infectious Diseases -- Responses
What you will learn:
·            The role of an integrated health system specialty pharmacist within the infectious disease clinic
·            A provider’s perspective of the benefits and challenges of integrating a pharmacist into a specialty clinic
·            How integrated health system specialty pharmacist affect specialty medication access, provider workload, and patient satisfaction
Learn more about your ad choices. Visit megaphone.fm/adchoices

Risk-based Care Can Drive Better Patient Adherence

Risk-based Care Can Drive Better Patient Adherence
Participants and Roles:          Sheila Arquette, President & CEO, NASP, Host/Interviewer                           
Purpose: Discuss how implementing risk-based care benefits patients and can improve their adherence rates
Ashleigh Burdette, MSN, RN, is the Sr. Director of Clinical Innovation with Biologics by McKesson. Ashleigh has been a Registered Nurse for nearly 15 years and holds a Master of Science in Nursing with a specialization in leadership and administration. She began her nursing career as an oncology nurse working in both bone marrow transplant and an outpatient clinic. In 2015, she joined Optum/United Health Group to focus on oncology patient support, utilization review, and clinical case management. In 2017, she joined Cardinal Health’s hub business and had the opportunity to lead both clinical operations and account management. Ashleigh joined Biologics by McKesson in 2020 to lead cross-functional collaboration to create customized patient management solutions that support the holistic needs of patients.
·            What is risked-based care, and how does it differ from “standardized care”?
·            What’s the methodology behind risked-based care?
·            Is the nurse-patient connection important? Why or why not?
·            What are some outcomes you’ve seen with this type of personalized level of care and support?
·            If someone wanted to implement this type of tailored support in their care setting, what are some of the essential components to keep in mind?
Contact the NASP: https://naspnet.org/about
Learn more about your ad choices. Visit megaphone.fm/adchoices

Package Performance Qualification – What it Is, Why it’s Important and How it Works | NASP Podcast

Topic: Package Performance Qualification (PPQ) Testing for URAC 4.0 Compliance & PBM Contracting
Participants and Roles:          
Sheila Arquette, President & CEO, NASP, Host/Interviewer
Katie Kraverath, Sr. Business Development Manager, Temptime Corporation
Bill Barrows, Program Director, Partner’s Healthcare Specialty Pharmacy
What you’ll learn:
Why it’s important to perform seasonal package performance qualification (PPQ) testing.
URAC and PBM requirements for PPQ Testing.
Processes and methods of testing, including third-party testing vs in-house testing.
An overview of changes to PPQ testing requirements per URAC’s new 4.0 version.
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices